Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH) - Completed Enrollment for Olorinab Study for Pain Associated with Crohn's Disease; Data in Q3:18 - Submitted Etrasimod Meeting Request to the FDA for Ulcerative Colitis (UC) SAN DIEGO , Aug.
View HTML
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
SAN DIEGO , July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018 , after the close of the U.S.
View HTML
Toggle Summary Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ
<p><strong>WOODCLIFF LAKE, N.J., JULY 17, 2018 – </strong>Eisai Inc. announced positive topline results from the <a href="https://clinicaltrials.gov/ct2/show/NCT02019264">CAMELLIA-TIMI 61</a> cardiovascular outcome trial. This 12,000 patient study of BELVIQ<strong><sup>®</sup></strong> (lorcaserin HCl) CIV 10 mg twice-daily was conducted at over 400 sites in eight countries including the United States in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is the largest cardiovascular (CV) outcome trial to date for a weight loss medication.</p>
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
SAN DIEGO , July 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
SAN DIEGO , May 21, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced&nbsp;that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , May 10, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced&nbsp;that Amit D. Munshi , President and Chief Executive Officer, will present at the following investor conferences: Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV on Thursday, May
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results
- Achieved positive Phase 2 results for etrasimod in ulcerative colitis in March; Phase 3 preparations for ulcerative colitis and a development plan for Crohn's disease underway - Expect to initiate Phase 3 studies for ralinepag in pulmonary arterial hypertension in second half of 2018 SAN DIEGO ,
View HTML
Toggle Summary Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
SAN DIEGO , May 2, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018 , after the close of the U.S.
View HTML
Toggle Summary Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders SAN DIEGO and INDIANAPOLIS , May 1, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused
View HTML
Toggle Summary Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
SAN DIEGO , April 12, 2018 /PRNewswire/ --&nbsp; Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist
View HTML